Seres Therapeutics reports positive topline results from SER-287 phase 1b study in patients with ulcerative colitis
- Category: DNA RNA and Cells
- Published on Tuesday, 03 October 2017 13:08
- Hits: 682
– SER-287 microbiome treatment resulted in a dose-dependent benefit in clinical remission rates, and an improvement in endoscopic scores –
– No clinically significant safety or tolerability findings were observed –
– Company intends to rapidly advance SER-287 to further development for Ulcerative Colitis –
CAMBRIDGE, MA, USA I October 2, 2017 I Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced positive topline results from a SER-287 Phase 1b placebo-controlled induction study in 58 patients with mild-to-moderate Ulcerative Colitis (UC), who were failing current therapies. Study data demonstrate that SER-287, a microbiome therapy containing a consortium of live bacterial spores, resulted in a benefit in clinical remission rates, and also an improvement in mucosal appearance by endoscopy. The SER-287 safety and tolerability profile, a co-primary study endpoint, demonstrated no clinically significant safety findings. Microbiome study results, a co-primary endpoint, are expected in the coming months.
“We are extremely pleased with these SER-287 Phase 1b efficacy and safety study results. The clinical data demonstrate the potential for microbiome therapeutics to provide an effective and safer alternative treatment modality for patients suffering from Ulcerative Colitis,” said Roger J. Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres. “Based on the strength of these data, Seres intends to work expeditiously to advance SER-287 into more advanced development studies. We plan to further evaluate SER-287 in mild, moderate and severe forms of Ulcerative Colitis, in maintenance after induction therapy, and we also intend to assess development in Crohn’s disease, and pediatric forms of inflammatory bowel disease. We expect to discuss these data with the FDA as soon as possible, to determine the most accelerated path to advance SER-287 development.”
“New treatment modalities are urgently needed that both address the inadequate levels of remission with available Ulcerative Colitis therapies, and have a favorable safety profile. The dose dependent and highly positive clinical remission rates and endoscopic scores from this study are very encouraging. SER-287 may represent an important new treatment option for patients,” said Stephen B. Hanauer, M.D., Professor of Medicine, Gastroenterology and Hepatology, Feinberg School of Medicine at Northwestern University, Chicago, Illinois.
The SER-287 Phase 1b study, a randomized, double-blinded, placebo-controlled, multiple-dose, induction study enrolled patients with mild-to-moderate Ulcerative Colitis, with Mayo scores of 4 to 10. The study enrolled 58 patients at 20 sites across the United States. Twenty-four patients were classified as having mild disease, and 33 patients had moderate disease. Study subjects exhibited pre-study disease activity despite use of current therapies in a majority of subjects, which included 5-amino-salacylic acid, low dose corticosteroids, or immunomodulatory therapy.
Patients were randomly assigned to one of three SER-287 treatment arms or a placebo arm for an eight-week treatment period. SER-287 arms included a daily dosing arm with vancomycin pre-treatment, a weekly dosing arm, and a weekly dosing arm with vancomycin pre-treatment. The co-primary study objectives were to evaluate safety and tolerability, and the change in the microbiome at up to 8 weeks after dosing. The secondary efficacy endpoints included clinical remission rates, endoscopic improvement and clinical response, assessed by a total modified Mayo score and endoscopy, which, of importance utilized a central reader. The Mayo score includes measures of stool frequency, rectal bleeding, the physician’s global assessment, and an endoscopic evaluation. Regulatory guidance from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for Ulcerative Colitis, both issued in 2016, recommends the use of clinical remission, including endoscopic improvement, as the primary endpoint in all registrational studies.
Efficacy and Safety Results
Study efficacy related analysis is based on intent to treat ‘observed case’ data in 53 patients. Eight-week results demonstrate that SER-287 administration resulted in a dose dependent improvement of clinical remission rates and an improvement in endoscopic scores. Data suggest that the most significant treatment effect occurred in patients treated with the daily dose of SER-287. Vancomycin addition to the regimen did not clearly alter efficacy effects.
Summary of efficacy results:
|Endpoint||Intent to Treat Population, Observed Case: Treatment Group|
|Placebo / Placebo
(N = 10) (%)
(N = 15) (%)
|Placebo / SER-287
(N = 14) (%)
(N = 14) (%)
|Clinical Remission1||1/10 (10.0)4||6/15 (40.0)||2/14 (14.3)||3/14 (21.4)|
|Difference from placebo (SER-287 minus placebo)||30.0%||4.3%||11.4%|
|Endoscopic Improvement2||1/10 (10.0)||6/15 (40.0)||5/14 (35.7)||4/14 (28.6)|
|Difference from placebo (SER-287 minus placebo)||30.0%||25.7%||18.6%|
|Clinical Response3||6/10 (60.0)||9/15 (60.0)||6/14 (42.9)||4/14 (28.6)|
|Difference from placebo (SER-287 minus placebo)||0.0%||-17.1%||-31.4%|
|1.||Clinical remission was defined as a total modified Mayo score of less than or equal to 2, and an endoscopic sub-score of 0 or 1.|
|2.||Endoscopic improvement was defined as a decrease in endoscopic sub score of greater than or equal to 1. Endoscopy measures were analyzed by a Central Reader|
|3.||Clinical response was defined as a decrease of 3 or more points in total modified Mayo score from baseline along with either a decrease of greater than or equal to 1 point in the rectal bleeding sub score, or an absolute rectal bleeding sub score of 0 or 1. Clinical response did not require a change in endoscopic score.|
|4.||A patient in the placebo study arm experienced a disease flare and was treated with corticosteroids prior to the end of treatment endoscopy. Endoscopy showed improvement and the patient was assessed as having achieved clinical remission.|
Diverse analyses of microbiome data of patients in this trial, a co-primary endpoint, are expected to be completed in the coming months. Three SER-287 drug product lots, based on human donor material obtained from three separate individuals, were used in the Phase 1b study. Microbiome analyses will also be conducted to determine whether there are any recognizable differences in the drivers of response across the drug product lots.
An evaluation of SER-287 safety and tolerability was a co-primary study endpoint. The company believes the SER-287 safety and tolerability profile was very favorable, and study results demonstrated no imbalance in adverse events in SER-287 treated patients, as compared to patients treated with placebo. There were no drug related serious adverse events associated with SER-287.
The Company intends to present detailed study results at a future medical/scientific meeting.
In addition to SER-287, Seres’ inflammatory bowel disease microbiome pipeline includes SER-301, a therapeutic candidate comprised of a consortium of rationally selected, fermented bacterial species. The pending SER-287 microbiome data will be used to inform the final composition of SER-301, as the Company plans a SER-301 Investigational New Drug (IND) application.
Conference Call Information
Seres management will host a conference call today, October 2, 2017, at 8:00 a.m. ET. A webcast of the conference call, as well as accompanying slides, may be accessed in the Investors & Media section of Seres’ website at www.serestherapeutics.com. To participate in the conference call, please dial (844) 277-9450 (domestic) or (336) 525-7139 (international) and provide conference ID number 94507828.
SER‐287 is a biologically sourced, oral formulation containing a consortium of live bacterial spores that is being developed for Ulcerative Colitis and other forms of inflammatory bowel disease. SER-287 is hypothesized to act through a novel mechanism of action by modulating the dysbiotic microbiome, reducing inflammation without immunosuppression effects. A healthy microbiome has been shown to maintain the integrity of the colonic barrier, reduce the signaling by pro-inflammatory molecules produced by certain bacteria, and induce regulatory T cells in the colon to modulate immune responses.1
About Ulcerative Colitis
Ulcerative Colitis is a serious chronic condition affecting approximately 700,000 individuals in the United States. The disease results in inflammation of the colon and rectum and can cause debilitating symptoms, including abdominal pain, bowel urgency, and diarrhea. Severe cases of Ulcerative Colitis may result in surgical removal of the colon.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform Company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection.
|1.||Blander JM et al., Regulation of inflammation by microbiota interactions with the host, Nature Immunology, 2017. Lynch S and Pedersen O, The Human Intestinal Microbiome in Health and Disease, The New England Journal of Medicine, 2016.|
SOURCE: Seres Therapeutics